Sprucegrove Investment Management Ltd. Decreases Stock Position in Gilead Sciences, Inc. $GILD

Sprucegrove Investment Management Ltd. trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 64.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 59,870 shares of the biopharmaceutical company’s stock after selling 107,500 shares during the period. Gilead Sciences comprises approximately 0.9% of Sprucegrove Investment Management Ltd.’s holdings, making the stock its 10th biggest holding. Sprucegrove Investment Management Ltd.’s holdings in Gilead Sciences were worth $7,348,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of GILD. Massachusetts Financial Services Co. MA increased its holdings in shares of Gilead Sciences by 3,763.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after buying an additional 4,113,999 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Gilead Sciences by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after acquiring an additional 2,113,692 shares during the last quarter. First Trust Advisors LP grew its position in Gilead Sciences by 154.3% in the third quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock worth $342,910,000 after acquiring an additional 1,874,508 shares in the last quarter. Invesco Ltd. increased its stake in Gilead Sciences by 12.0% in the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock valued at $1,680,505,000 after acquiring an additional 1,618,453 shares during the last quarter. Finally, Danske Bank A S bought a new position in Gilead Sciences in the third quarter valued at $133,049,000. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

GILD has been the subject of a number of recent research reports. Mizuho boosted their target price on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Jefferies Financial Group assumed coverage on shares of Gilead Sciences in a research note on Tuesday, March 10th. They set a “buy” rating and a $180.00 price target on the stock. Morgan Stanley boosted their price objective on shares of Gilead Sciences from $171.00 to $175.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. UBS Group upped their price objective on shares of Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, Cantor Fitzgerald decreased their target price on shares of Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, April 10th. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $157.35.

Gilead Sciences Stock Up 0.6%

Shares of NASDAQ:GILD opened at $133.48 on Wednesday. The firm has a market capitalization of $165.68 billion, a P/E ratio of 19.72, a P/E/G ratio of 1.75 and a beta of 0.31. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The stock has a 50 day moving average price of $140.14 and a 200-day moving average price of $132.66. Gilead Sciences, Inc. has a 52-week low of $95.29 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same period last year, the business earned $1.90 EPS. Gilead Sciences’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 8.62 EPS for the current fiscal year.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: AHF says Gilead’s EPS could rise ~52% because state AIDS drug program shortfalls have increased reliance on commercial/retail supply, implying near-term revenue upside for Gilead’s HIV portfolio. Gilead’s Earnings Skyrocket as Florida’s AIDS Drug Program Falters, says AHF
• Positive Sentiment: Brokerage commentary and price-target coverage are constructive — a recent note cites a $157.35 target, supporting investor expectations of upside versus current levels. Brokerages Set Gilead Sciences, Inc. (NASDAQ:GILD) Price Target at $157.35
• Neutral Sentiment: Use of Yeztugo (twice-yearly HIV-prevention shot) is rising since launch, which supports Gilead’s growth story in prevention, but adoption is still early and incremental to overall revenues. Focus: Use of Gilead’s HIV prevention shot rises, but US insurance gaps remain
• Neutral Sentiment: Analyst/estimate deep dives (Zacks/market write-ups) are circulating ahead of quarterly reporting; these pieces highlight key metrics investors will watch (sales mix of HIV products, hepatitis/oncology performance, and guidance). That keeps focus on fundamentals rather than a single headline. Curious about Gilead (GILD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
• Neutral Sentiment: Brand/marketing recognition (PLAN C Impact 50) is positive for awareness but unlikely to move near-term fundamentals materially. Eight PLAN C Client Brands Named to the 3AF 2026 Impact 50
• Negative Sentiment: Insurance coverage gaps for Yeztugo remain a real constraint — patients who want the injection can face reimbursement hurdles, which could cap upside in medium-term prevention revenue if not resolved. Use of Gilead’s HIV prevention shot rises, but US insurance gaps remain

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the transaction, the chief financial officer directly owned 176,191 shares of the company’s stock, valued at approximately $24,835,883.36. This represents a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total value of $17,346,000.00. Following the sale, the chief executive officer directly owned 613,912 shares in the company, valued at $92,086,800. This trade represents a 15.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 178,640 shares of company stock worth $26,584,250. Corporate insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.